Patent · US Active

Method of treatment for neutropenia using stable formulations of recombinant human albumin-human granulocyte colony stimulating factor

US8993519B2 · kind B2 · utility

0Cited by
20References
26Claims
0Family size

Assignee

Inventors

Key dates

Filing dateOct 25, 2012
Grant dateMar 31, 2015
Priority date
Expiry dateFeb 28, 2033

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61P43/00
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Described herein are compositions and methods for treating, preventing and ameliorating diseases and conditions characterized by a lower than normal white blood cell count, such as leukopenia and neutropenia. The compositions and methods include recombinant human albumin-human granulocyte colony stimulating factor. Pharmaceutical formulations including the recombinant fusion protein, and methods of making such formulations are also described.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.